Filing summary
Issuer and period: The supplied filing is Onconova Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2016, filed March 29, 2017. This does not match the request metadata identifying Traws Pharma, Inc.; verify the intended issuer. The company’s share and per-share figures reflect a 1-for-10 reverse split effective May 31, 2016.
Business context and development
Onconova was a clinical-stage biopharmaceutical company with no approved products or product-sale revenue. Most resources were focused on rigosertib, including the Phase 3 INSPIRE trial of intravenous rigosertib in higher-risk MDS patients after HMA failure, and development of oral rigosertib with azacitidine. Other programs included briciclib, on clinical hold, and recilisib, whose development depended on government funding or collaboration.
Financial results and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $5.5 million | $11.5 million |
| Research and development expense | $20.1 million | $25.9 million |
| General and administrative expense | $9.2 million | $9.5 million |
| Operating loss | $23.7 million | $24.0 million |
| Net loss | $19.7 million | $24.0 million |
| Net loss per share | $4.44 | $10.54 |
| Cash used in operating activities | $15.8 million | $31.2 million |
| Cash and cash equivalents at year-end | $21.4 million | $19.8 million |
2016 revenue was entirely from collaboration and funding arrangements, not product sales. Revenue fell 52%, chiefly because the company recognized $8.0 million of Leukemia and Lymphoma Society funding in 2015; increased Baxalta trial-cost reimbursements partly offset the decline. Operating expenses fell 17%, mainly from reduced development spending. Net loss improved partly because a $4.0 million noncash decrease in warrant-liability fair value was recorded as income; operating loss was nearly unchanged.
At year-end, current assets were $23.1 million and current liabilities $10.2 million. Total liabilities were $18.1 million, including a $3.4 million warrant liability; the balance sheet reports no conventional borrowings. Stockholders’ equity was $5.1 million and accumulated deficit was $338.2 million. Financing activities provided $17.4 million in 2016, primarily from equity and warrant offerings. The filing states cash was expected to fund ongoing trials and operations into the fourth quarter of 2017, but not to complete INSPIRE or a Phase 3 combination trial.
Changes, outlook, risks, and unusual items
- The Baxalta European license agreement ended August 30, 2016. European rights reverted to Onconova, but cost-sharing, milestones, and potential royalties ended; Baxalta had contributed $5.0 million toward INSPIRE costs in 2016.
- Management expected 2017 cash expenditures to increase as INSPIRE sites and enrollment expanded and Baxalta support ceased. A 12-person workforce reduction generated approximately $3.0 million of severance-related charges, including $1.4 million noncash accelerated stock-option vesting; savings were expected to be fully realized in 2017.
- INSPIRE targeted an interim analysis in the second half of 2017 and full enrollment by the first quarter of 2018; topline results were anticipated in 2018. The interim review could lead to continuation, restricted enrollment, futility termination, or a larger sample size.
- For oral rigosertib plus azacitidine, the company planned to submit a Phase 3 protocol for regulatory review in the second or third quarter of 2017. It stated that the trial would not begin without additional financing. The prior Phase 2 analysis reported an overall IWG response rate of 76% among 33 evaluable patients; this is preliminary clinical evidence, not confirmatory Phase 3 efficacy.
- The prior Phase 3 ONTIME trial of IV rigosertib missed its primary overall-survival endpoint. INSPIRE enrollment was described as selective and dependent on stringent eligibility criteria. Reported treatment risks included serious infections and blood-related adverse events; oral monotherapy also had urinary side effects.
- The auditor issued an unmodified opinion on the financial statements but included an explanatory paragraph stating substantial doubt about the company’s ability to continue as a going concern. Management likewise identified substantial doubt and said additional financing was required; absent funding, programs could be delayed, scaled back, licensed, or stopped.
- Equity financing and outstanding warrants create dilution risk. Common shares outstanding rose from 2.55 million at year-end 2015 to 6.76 million at year-end 2016; 3.53 million warrants and 746,353 options were outstanding at year-end 2016.
Important facts for investors to verify
- Confirm that Onconova’s 2016 10-K, rather than a Traws Pharma filing, is the intended document.
- Check subsequent filings for actual cash runway, financing raised, and any resulting dilution or changes to the going-concern assessment.
- Verify INSPIRE enrollment, interim-analysis outcome, trial funding, and the status and financing of the proposed combination Phase 3 trial.
- Review the consequences of Baxalta’s termination for development funding and any later collaboration or licensing arrangements.
- Assess the clinical evidence and safety disclosures against later trial results; the filing’s Phase 2 response data and management timelines are not guarantees of approval or success.